Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Kratky, M.; Vinsova, J.
    Advances in mycobacterial isocitrate lyase targeting and inhibitors (2012), Curr. Med. Chem., 19, 6126-6137.
    View publication on PubMed

Application

EC Number Application Comment Organism
4.1.3.1 drug development the enzyme is a target for anti-mycobacterial drug development Mycobacterium tuberculosis

Inhibitors

EC Number Inhibitors Comment Organism Structure
4.1.3.1 1-cyclopropyl-7-[3,5-dimethyl-4-(3-nitropropanoyl)piperazin-1-yl]-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid a fluoroquinolone derivative and structural analogue of succinate Mycobacterium tuberculosis

Organism

EC Number Organism UniProt Comment Textmining
4.1.3.1 Mycobacterium tuberculosis
-
-
-

IC50 Value

EC Number IC50 Value IC50 Value Maximum Comment Organism Inhibitor Structure
4.1.3.1 0.0001
-
 pH and temperature not specified in the publication Mycobacterium tuberculosis 1-cyclopropyl-7-[3,5-dimethyl-4-(3-nitropropanoyl)piperazin-1-yl]-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

General Information

EC Number General Information Comment Organism
4.1.3.1 physiological function isocitrate lyase plays a key role for survival of Mycobacterium tuberculosis in the latent form during a chronic stage of infection. The enzyme is important during steady stage growth when it converts isocitrate to succinate and glyoxylate Mycobacterium tuberculosis